Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://www.ncbi.nlm.nih.gov/pubmed/27959342
http://dx.doi.org/10.1038/ncomms13122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://www.ncbi.nlm.nih.gov/pubmed/27959342
http://dx.doi.org/10.1038/ncomms13122

Ejemplares similares